◆英語タイトル:X-Chem Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013424
◆発行会社(調査会社):
GlobalData
◆発行日:2017年11月28日
◆ページ数:39
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
X-Chem Inc (X-Chem) is a biotechnology company that focuses on applying its innovative drug discovery platform to the generation of novel small molecule therapeutics. The company’s drug discovery engine is based on a library generated by iterative combinatorial synthesis of small molecules. It covers a range of categories including fragment molecules, small molecular weight heterocyclic compounds, and macrocyclic structures. X-Chem established collaborations with pharmaceutical companies including Roche, AstraZeneca, Bayer, Pfizer, among others. The company also has partnerships with biotechnology companies, academic centers and non-profit institutions. X-Chem Inc is a subsidiary of Pharmaceutical Product Development LLC. It is headquartered in Waltham, Massachusetts, the US.
X-Chem Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
X-Chem Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
X-Chem Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
X-Chem Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
X-Chem Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
X-Chem Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
X-Chem Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
X-Chem Enters into Agreement with Vertex Pharma 11
X-Chem Enters into Agreement with Ono Pharma 12
X-Chem Enters into Agreement with Astellas Pharma 13
X-Chem Enters into Agreement with Taiho Pharma 14
X-Chem Enters into Co-Development Agreement with AbbVie 15
X-Chem Enters into Agreement with Sanofi 16
X-Chem Enters into Agreement with University of Texas MD Anderson Cancer Center 17
X-Chem Expands Agreement with Janssen Biotech 18
Navitor Pharma Enters into Agreement with X-Chem 19
X-Chem Enters into Discovery Agreement with Alexion Pharma 20
X-Chem Enters into Co-Development Agreement with Pfizer 21
X-Chem Enters Into Agreement With PsyBrain To Discover Psychiatric Medicines 22
X-Chem Extends Drug Discovery Agreement With AstraZeneca 23
Pharmaceutical Product Development and X-Chem Form Joint Venture 24
X-Chem and Bayer Pharma Expand Agreement 25
X-Chem Enters Into Drug Discovery Agreement With AstraZeneca 26
Licensing Agreements 27
Navitor Pharma Exercises Option for Licensing Agreement with X-Chem 27
Janssen Biotech Exercises Option for Licensing Agreement with X-Chem 28
X-Chem Enters into Licensing Agreement with Bayer Pharma for Drug Discovery Program 29
Bayer Pharma Enters Into Licensing Agreement With X-Chem For Drug Discovery Program 30
AstraZeneca Enters Into Licensing Agreement With X-Chem For Three Drug Discovery Programs 31
Acquisition 32
Pharmaceutical Product Development Exercises Option to Acquire Remaining 36% Stake in X-Chem 32
Pharma Product Development Acquires 64% Stake In X-Chem For US$15.5 Million 33
X-Chem Inc – Key Competitors 34
X-Chem Inc – Key Employees 35
X-Chem Inc – Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Recent Developments 37
Strategy And Business Planning 37
Jan 06, 2016: X-Chem Established as Independent, Privately Owned Biotechnology Company 37
Government and Public Interest 38
Oct 31, 2017: Consortium of X-Chem, Harvard T.H. Chan School of Public Health and Other Leading Academic Institutions Wins Research Award from the Department of Defense 38
Appendix 39
Methodology 39
About GlobalData 39
Contact Us 39
Disclaimer 39
List of Tables
X-Chem Inc, Pharmaceuticals & Healthcare, Key Facts 2
X-Chem Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
X-Chem Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
X-Chem Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
X-Chem Inc, Deals By Therapy Area, 2011 to YTD 2017 8
X-Chem Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
X-Chem Enters into Agreement with Vertex Pharma 11
X-Chem Enters into Agreement with Ono Pharma 12
X-Chem Enters into Agreement with Astellas Pharma 13
X-Chem Enters into Agreement with Taiho Pharma 14
X-Chem Enters into Co-Development Agreement with AbbVie 15
X-Chem Enters into Agreement with Sanofi 16
X-Chem Enters into Agreement with University of Texas MD Anderson Cancer Center 17
X-Chem Expands Agreement with Janssen Biotech 18
Navitor Pharma Enters into Agreement with X-Chem 19
X-Chem Enters into Discovery Agreement with Alexion Pharma 20
X-Chem Enters into Co-Development Agreement with Pfizer 21
X-Chem Enters Into Agreement With PsyBrain To Discover Psychiatric Medicines 22
X-Chem Extends Drug Discovery Agreement With AstraZeneca 23
Pharmaceutical Product Development and X-Chem Form Joint Venture 24
X-Chem and Bayer Pharma Expand Agreement 25
X-Chem Enters Into Drug Discovery Agreement With AstraZeneca 26
Navitor Pharma Exercises Option for Licensing Agreement with X-Chem 27
Janssen Biotech Exercises Option for Licensing Agreement with X-Chem 28
X-Chem Enters into Licensing Agreement with Bayer Pharma for Drug Discovery Program 29
Bayer Pharma Enters Into Licensing Agreement With X-Chem For Drug Discovery Program 30
AstraZeneca Enters Into Licensing Agreement With X-Chem For Three Drug Discovery Programs 31
Pharmaceutical Product Development Exercises Option to Acquire Remaining 36% Stake in X-Chem 32
Pharma Product Development Acquires 64% Stake In X-Chem For US$15.5 Million 33
X-Chem Inc, Key Competitors 34
X-Chem Inc, Key Employees 35
X-Chem Inc, Other Locations 36